To study Mucormycosis epidemiology in India
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients who diagnosed with MucormycosisHealth Condition 2: B46- Zygomycosis
- Registration Number
- CTRI/2016/02/006644
- Lead Sponsor
- MYLAN PHARMACEUTICALS PRIVATE LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 465
Inclusion Criteria
Any age group of patients with confirmed & probable diagnosis of Mucormycosis will be enrolled for this study
Exclusion Criteria
Any subject without a confirmed diagnosis of mucormycosis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Overall survival at 45 and 90 days <br/ ><br>2.Cure: defined as complete resolution of clinical, radiological and mycological evidence <br/ ><br>3.Improved: Resolution of clinical features, radiological regression <br/ ><br>outcome of mucormycosis in IndiaTimepoint: 45 and 90 days
- Secondary Outcome Measures
Name Time Method Grade III and IV toxicities of antifungal agentsTimepoint: 45 days